Profile of lebrikizumab and its potential in the treatment of asthma

Medicine and Dentistry

• Interleukin 13 100%
• Combination Therapy 60%
• Asthma 60%
• Transcription Factor RUNX2 40%
• Disease Marker 40%
• Treatment of Asthma 40%
• Receptor 20%
• Protein 20%
• Monoclonal Antibody 20%
• Cell Type 20%
• Serositis 20%
• Mediator 20%
• Fibrosis 20%
• Immunoglobulin E 20%
• Interleukin 4 20%
• Airway Remodeling 20%
• Patient 20%
• T-Helper Cell 20%
• Lung Function 20%
• Eosinophil 20%

Immunology and Microbiology

• Asthma 100%
• Interleukin 13 100%
• Lebrikizumab 80%
• Transcription Factor RUNX2 40%
• Monoclonal Antibodies 20%
• Immunoglobulin E 20%
• Mediator 20%
• Interleukin 4 20%
• T Helper Cell 20%
• Eosinophil Count 20%
• Electric Potential 20%
• Inflammation 20%
• Lung Function 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Interleukin 13 100%
• Lebrikizumab 80%
• Asthma 60%
• Disease Marker 40%
• Transcription Factor RUNX2 40%
• Receptor 20%
• Protein 20%
• Monoclonal Antibody 20%
• Fibrosis 20%
• Immunoglobulin E 20%
• Interleukin 4 20%
• Airway Remodeling 20%